Pharma Stocks To Buy 2017 ✯ (PRO)

: Delivered a 516% return as it dominated its niche in the metabolic disease market.

: Gained 103% , evolving from a rare-disease specialist into a large-cap biotech giant. Blue-Chip & Dividend Leaders

: Soared over 440% after announcing a gene therapy partnership with Pfizer . pharma stocks to buy 2017

: Maintained its lead in prescription sales and remained a "Strong Buy" due to its robust clinical pipeline and steady dividend.

: Held its position as the world's largest pharma company by market cap ($387B in 2017). ⚠️ Key Trends & Risks : Delivered a 516% return as it dominated

While 2017 was a banner year, several headwinds shaped investment strategies: Pharm Exec's Top 50 Companies 2017 | PharmExec

In , the pharmaceutical sector outperformed the broader market, with the SPDR S&P Biotech ETF (XBI) surging approximately 40% , doubling the returns of the S&P 500 . This growth was fueled by significant FDA approvals and high-value partnerships between biotech startups and industry giants. 🚀 Top Performing Pharma & Biotech (2017) : Maintained its lead in prescription sales and

: Gained over 700% after positive Phase 2 data for its epilepsy treatment, ganaxolone.

Arrow Left Arrow Right
Slideshow Left Arrow Slideshow Right Arrow